AU2002238532A1 - Tripeptide derivatives for the treatment of postlesional diseases of the nervous system - Google Patents
Tripeptide derivatives for the treatment of postlesional diseases of the nervous systemInfo
- Publication number
- AU2002238532A1 AU2002238532A1 AU2002238532A AU2002238532A AU2002238532A1 AU 2002238532 A1 AU2002238532 A1 AU 2002238532A1 AU 2002238532 A AU2002238532 A AU 2002238532A AU 2002238532 A AU2002238532 A AU 2002238532A AU 2002238532 A1 AU2002238532 A1 AU 2002238532A1
- Authority
- AU
- Australia
- Prior art keywords
- sub
- alkoxy
- alkyl
- residue
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 210000000653 nervous system Anatomy 0.000 title 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 abstract 1
- 241000024188 Andala Species 0.000 abstract 1
- -1 cinnamoyl residue Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 230000000472 traumatic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10105040.2 | 2001-02-05 | ||
| DE10105040A DE10105040A1 (de) | 2001-02-05 | 2001-02-05 | Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems |
| PCT/EP2002/001182 WO2002062372A2 (en) | 2001-02-05 | 2002-02-05 | Tripeptide derivatives for the treatment of postlesional diseases of the nervous system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002238532A1 true AU2002238532A1 (en) | 2002-08-19 |
Family
ID=7672833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002238532A Abandoned AU2002238532A1 (en) | 2001-02-05 | 2002-02-05 | Tripeptide derivatives for the treatment of postlesional diseases of the nervous system |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7163922B2 (enExample) |
| EP (1) | EP1390055B1 (enExample) |
| JP (1) | JP2004526701A (enExample) |
| AT (1) | ATE310529T1 (enExample) |
| AU (1) | AU2002238532A1 (enExample) |
| DE (2) | DE10105040A1 (enExample) |
| DK (1) | DK1390055T3 (enExample) |
| ES (1) | ES2250617T3 (enExample) |
| WO (1) | WO2002062372A2 (enExample) |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU599809B2 (en) * | 1987-05-20 | 1990-07-26 | Zambon Group S.P.A. | Isoxazoles with nootropic activity |
| CA1323301C (en) | 1987-06-05 | 1993-10-19 | Alan I. Faden | Thyrotropin-releasing hormone analogs in cns injury |
| FR2622581B1 (fr) * | 1987-11-03 | 1990-02-16 | Inorgan Sa Rech Develop Pharm | Nouveaux derives de l-proline, leur preparation et leurs applications biologiques |
| HU904967D0 (en) * | 1988-04-22 | 1991-01-28 | Hoechst Ag | Process for producing new azabicyclo(3.3.o)octane-3-carboxylic acid-octylesther derivatives |
| DE4007869A1 (de) | 1990-03-13 | 1991-09-19 | Merck Patent Gmbh | Aminosaeurederivate |
| JPH045240A (ja) | 1990-04-20 | 1992-01-09 | Taisho Pharmaceut Co Ltd | 抗痴呆剤 |
| JPH06504061A (ja) | 1990-12-28 | 1994-05-12 | コーテックス ファーマシューティカルズ インコーポレイテッド | 神経変性の治療および予防におけるカルパイン阻害剤の使用 |
| WO1992013549A1 (en) * | 1991-02-07 | 1992-08-20 | Research Corporation Technologies, Inc. | Inhibition of cell proliferation by hydrophobic peptides |
| US6235929B1 (en) * | 1991-12-27 | 2001-05-22 | Georgia Tech Research Corporation | Tripeptide α-ketoamides |
| US5716929A (en) * | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5834029A (en) * | 1994-07-20 | 1998-11-10 | Cytotherapeutics, Inc. | Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment |
| EP0840614A1 (en) | 1995-06-13 | 1998-05-13 | Sanofi Winthrop, Inc. | Calpain inhibitors for the treatment of neurodegenerative diseases |
| US5840838A (en) * | 1996-02-29 | 1998-11-24 | University Of Kentucky Research Foundation | Process for enhancing the activity of amyloid β peptides |
| JP2001501930A (ja) | 1996-10-04 | 2001-02-13 | オークランド ユニサーヴィスィズ リミテッド | 神経酵素の調節 |
| JP4727770B2 (ja) * | 1997-09-26 | 2011-07-20 | カルピス株式会社 | 尿中カテコールアミン低下、尿中ノルアドレナリン低下、尿中ドーパミン低下及びＦｉｓｃｈｅｒ比低下の少なくとも１つの軽減剤 |
| US6080848A (en) * | 1998-05-01 | 2000-06-27 | Incyte Pharmaceuticals, Inc. | Human brain associated protein |
| US6379691B1 (en) * | 1998-09-29 | 2002-04-30 | Medtronic/Ave, Inc. | Uses for medical devices having a lubricious, nitric oxide-releasing coating |
| AU1574701A (en) * | 1999-10-22 | 2001-04-30 | Wrair Walter Reed Army Institute Of Research | A pharmaceutical composition containing pglu-glu-pro-nh2 and method for treating diseases and injuries to the brain, spinal cord and retina using same |
| JP4633876B2 (ja) * | 1999-11-11 | 2011-02-16 | カルピス株式会社 | トリペプチドの製造方法 |
| WO2001068114A1 (en) | 2000-03-10 | 2001-09-20 | Monsanto Company | Novel peptides with anti-hypertensive activity |
| DE10105041A1 (de) * | 2001-02-05 | 2002-08-14 | Tell Pharm Ag Hergiswil | Tripeptide und Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten |
| DE10105038B4 (de) * | 2001-02-05 | 2005-07-07 | Neurotell Ag | Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems |
-
2001
- 2001-02-05 DE DE10105040A patent/DE10105040A1/de not_active Ceased
-
2002
- 2002-02-05 AU AU2002238532A patent/AU2002238532A1/en not_active Abandoned
- 2002-02-05 JP JP2002562378A patent/JP2004526701A/ja active Pending
- 2002-02-05 DE DE60207550T patent/DE60207550T2/de not_active Expired - Lifetime
- 2002-02-05 DK DK02704686T patent/DK1390055T3/da active
- 2002-02-05 EP EP02704686A patent/EP1390055B1/en not_active Expired - Lifetime
- 2002-02-05 ES ES02704686T patent/ES2250617T3/es not_active Expired - Lifetime
- 2002-02-05 AT AT02704686T patent/ATE310529T1/de not_active IP Right Cessation
- 2002-02-05 WO PCT/EP2002/001182 patent/WO2002062372A2/en not_active Ceased
-
2003
- 2003-08-05 US US10/635,808 patent/US7163922B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE310529T1 (de) | 2005-12-15 |
| EP1390055A2 (en) | 2004-02-25 |
| EP1390055B1 (en) | 2005-11-23 |
| DK1390055T3 (da) | 2006-01-09 |
| US7163922B2 (en) | 2007-01-16 |
| JP2004526701A (ja) | 2004-09-02 |
| DE60207550T2 (de) | 2006-08-10 |
| ES2250617T3 (es) | 2006-04-16 |
| WO2002062372A3 (en) | 2004-01-08 |
| DE10105040A1 (de) | 2002-08-14 |
| DE60207550D1 (de) | 2005-12-29 |
| US20050101539A1 (en) | 2005-05-12 |
| WO2002062372A2 (en) | 2002-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107990T1 (el) | Τριπεπτιδια και παραγωγα τριπεπτιδιων για τη θepαπεια νευροεκφυλιστικων ασθενειων | |
| JPS56138155A (en) | Angiotensin-ii analogue and manufacture | |
| AU2003264514A1 (en) | Wt1 substitution peptides | |
| DE69912952D1 (en) | Cyclosporine | |
| AU633913B2 (en) | Novel tnf-inhibit proteins and their preparation | |
| AU5249898A (en) | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | |
| AU6020099A (en) | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein | |
| WO2002018321A3 (en) | Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors | |
| NO941151L (no) | Lineære adhesjonsinhibitorer | |
| WO2001027136A3 (fr) | Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire | |
| WO2002024213A3 (en) | Improved protocol for paracentesis | |
| WO2002062373A3 (en) | Tripeptides and tripeptide derivatives for the treatment of postlesional diseases of the nervous system | |
| CA2196308A1 (en) | Peptide, bronchodilator and blood flow ameliorant | |
| AU2002238532A1 (en) | Tripeptide derivatives for the treatment of postlesional diseases of the nervous system | |
| DE3569541D1 (en) | Pharmacologically active peptides | |
| WO2004046178A3 (en) | Shrew paralytic peptide for use in neuromuscular therapy | |
| EP1908781A3 (en) | Modulation of immune response and methods based thereon | |
| WO2002018323A3 (en) | Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors | |
| YU48997A (sh) | Novi biološki aktivni proteini, njihove farmaceutske smeše i postupak za njihovo dobijanje | |
| CA2102447A1 (en) | Cyclopeptides | |
| WO2001064715A3 (en) | Memno peptides, a process for their preparation and their use | |
| RU93050068A (ru) | Циклопептиды, способ их получения, фармацевтические композиции и способ их получения, способ лечения | |
| CA1284550C (en) | Retro-inverso analogs of the bradykinin potentiating peptide bpp*in5a*xx | |
| WO2002083729A3 (en) | Polypeptides derived from amyloid precursor peptide (app) and their uses | |
| AU2003264940A1 (en) | Pyrazole derivatives and their use as therapeutic agents for hiv mediated diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |